HC Wainwright reiterates Buy on Neurogene, keeps $70 target
HC Wainwright & Co. analyst Mitchell S. Kapoor has reiterated a Buy rating for Neurogene (NASDAQ: NGNE) and maintained a price target of $70.
*this image is generated using AI for illustrative purposes only.
HC Wainwright & Co. analyst Mitchell S. Kapoor has reaffirmed a Buy rating for Neurogene (NASDAQ: NGNE) while maintaining a price target of $70. The endorsement reflects continued confidence in the company's prospects.
Analyst Recommendation
Mitchell S. Kapoor, an analyst at HC Wainwright & Co., reiterated the firm's positive stance on Neurogene. The rating and price target remain unchanged following the review.
| Firm | Analyst | Rating | Price Target |
|---|---|---|---|
| HC Wainwright & Co. | Mitchell S. Kapoor | Buy | $70 |
What upcoming clinical milestones could drive Neurogene's stock toward the $70 price target?
How might recent advancements in gene therapy impact Neurogene's competitive positioning?
What are the potential regulatory hurdles Neurogene could face in the near term?
20
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
